Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

NCT07490002 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
33
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Changhai Hospital